|Bid||1.5600 x 1200|
|Ask||1.5700 x 1200|
|Day's Range||1.5000 - 1.5900|
|52 Week Range||0.6400 - 4.2400|
|Beta (5Y Monthly)||1.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.64|
Subscribe to Yahoo Finance Plus to view Fair Value for RIGL
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) and Forma Therapeutics Inc (NASDAQ: FMTX) entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib. Olutasidenib is an oral, small molecule inhibitor of mIDH1 being investigated for relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. The FDA has accepted Forma's marketing application for olutasidenib with the Prescription Drug User Fee Act target date of February 15, 2023. Relat
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.